{
    "4 23 2025": {
        "importantArticles": [
            {
                "headline": "The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030.  As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth.  Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8948",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?",
                "url": "https://finance.yahoo.com/news/whats-next-pfizer-company-pulls-104000218.html"
            },
            {
                "headline": "Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it\u2019s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "StockStory",
                "ticker": "PFE",
                "title": "3 of Wall Street\u2019s Favorite Stocks Walking a Fine Line",
                "url": "https://finance.yahoo.com/news/3-wall-street-favorite-stocks-130400724.html"
            },
            {
                "headline": "PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-q1-earnings-release-105800319.html"
            },
            {
                "headline": "NEW YORK, April 23, 2025--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO\u00ae) Annual Meeting, taking place May 30 to June 3 in Chicago. Data from more than 60 company-sponsored, investigator-sponsored, and collaborative research abstracts, including 9 oral presentations and 6 rapid oral presentations, will be presented across Pfizer\u2019s key tumor areas, including breast, genitourinary,",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7906",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting",
                "url": "https://finance.yahoo.com/news/pfizer-advances-bold-vision-future-194600237.html"
            },
            {
                "headline": "Passive income is essential in retirement, but building a dependable stream isn't easy.  Fortunately, top-tier dividend stocks can do the heavy lifting.  In today's volatile market, where uncertainty is the only constant, dividend investing has regained its shine.",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7012",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "2 High-Yield Dividend Stocks to Buy for Passive Income",
                "url": "https://finance.yahoo.com/news/2-high-yield-dividend-stocks-123000741.html"
            },
            {
                "headline": "Summit Therapeutics Inc.'s (NASDAQ:SMMT) partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression. HARMONi-6 is a study conducted in China sponsored",
                "publication_date": "2025-04-23T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Benzinga",
                "ticker": "PFE",
                "title": "Why Is Summit Therapeutics Stock Soaring On Wednesday?",
                "url": "https://finance.yahoo.com/news/why-summit-therapeutics-stock-soaring-194743694.html"
            }
        ],
        "avgScore": -0.019390909090909073,
        "pctChange": -0.017120337367930973
    },
    "4 22 2025": {
        "importantArticles": [
            {
                "headline": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6486",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
                "url": "https://finance.yahoo.com/news/investors-heavily-search-pfizer-inc-130014658.html"
            },
            {
                "headline": "Investing.com -- Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and blood sugar control comparable to injectable treatments like Ozempic.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Novo shares down on Eli Lilly\u2019s positive obesity pill data",
                "url": "https://finance.yahoo.com/news/novo-shares-down-eli-lilly-083401896.html"
            },
            {
                "headline": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for",
                "url": "https://finance.yahoo.com/news/analysts-estimate-pfizer-pfe-report-140058650.html"
            },
            {
                "headline": "We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other recent activist investor campaigns. Economic uncertainty and market volatility are some of the factors fueling activist investor campaigns in 2025. In the first quarter alone, there [\u2026]",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE): Among Recent Activist Investor Campaigns",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-among-recent-133604076.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Thoughts on These 5 Stocks. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discussed. On Thursday\u2019s episode of Mad Money, Jim Cramer addressed the growing friction between Federal Reserve Chairman Jerome Powell and [\u2026]",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3612",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Jim Cramer Warns on Pfizer (PFE): \u201cThat 7.7% Yield Is Not a Sign of Strength \u2013 It\u2019s a Sign of Weakness\u201d",
                "url": "https://finance.yahoo.com/news/jim-cramer-warns-pfizer-pfe-174450309.html"
            },
            {
                "headline": "Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.",
                "publication_date": "2025-04-22T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity Pill",
                "url": "https://finance.yahoo.com/m/e688a2ac-055a-3925-abe7-cd3cb5566982/novo-nordisk-pops-after.html"
            }
        ],
        "avgScore": 0.10198333333333331,
        "pctChange": -0.006213994351098935
    },
    "4 21 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors, often delivering stronger returns than the broader market over time. [\u2026]",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8779",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5%",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-one-safe-141911199.html"
            },
            {
                "headline": "SpringWorks Therapeutics and the Children\u2019s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "How a scrapped Pfizer drug became a winner for SpringWorks",
                "url": "https://finance.yahoo.com/news/scrapped-pfizer-drug-became-winner-080000858.html"
            },
            {
                "headline": "SpringWorks Therapeutics and the Children\u2019s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "How a scrapped Pfizer drug became a winner for SpringWorks",
                "url": "https://finance.yahoo.com/news/scrapped-pfizer-drug-became-winner-080000858.html"
            },
            {
                "headline": "We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors, often delivering stronger returns than the broader market over time. [\u2026]",
                "publication_date": "2025-04-21T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8779",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE): One of the Safe Dividend Stocks with Yields Above 5%",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-one-safe-141911199.html"
            }
        ],
        "avgScore": 0.42605,
        "pctChange": 0.0222322935918281
    },
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that equities around the world traded in and [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc.\u00a0(PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-best-large-185020270.html"
            },
            {
                "headline": "Tariff uncertainty has created an ideal opportunity for long-term investors to pounce.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now",
                "url": "https://finance.yahoo.com/news/trump-tariff-plunge-3-phenomenal-075100309.html"
            },
            {
                "headline": "Pfizer\u2019s Braftovi has received accelerated FDA approval for the treatment of BRAF V600E-mutated metastatic colorectal cancer patients due to its strong clinical benefits.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Clinical Trials Arena",
                "ticker": "PFE",
                "title": "Advances in BRAF colorectal cancer treatment further segment the paradigm",
                "url": "https://finance.yahoo.com/news/advances-braf-colorectal-cancer-treatment-160941995.html"
            },
            {
                "headline": "The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6597",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Vaccine Stocks Rise on Growing Threat of Bird Flu Infections",
                "url": "https://finance.yahoo.com/news/vaccine-stocks-rise-growing-threat-150800194.html"
            },
            {
                "headline": "The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59",
                "url": "https://finance.yahoo.com/news/gsk-pfes-rsv-vaccines-recommended-132000369.html"
            },
            {
                "headline": "Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week. This move is in line with broader market trends, as the market dropped by 3% during the same period. The company's decision to halt development of Danuglipron, an oral weight loss drug, due to safety concerns, may have also added weight to the downward pressure on its...",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3451",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention",
                "url": "https://finance.yahoo.com/news/pfizer-nyse-pfe-gets-cdc-172534992.html"
            }
        ],
        "avgScore": 0.11347,
        "pctChange": -0.004516643038745885
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "NEW YORK, April 16, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention\u2019s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO\u00ae (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug A",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "ACIP Votes to Expand Recommendation for Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Include Adults Aged 50 to 59 at Increased Risk of Disease",
                "url": "https://finance.yahoo.com/news/acip-votes-expand-recommendation-pfizer-201500828.html"
            },
            {
                "headline": "NEW YORK, April 16, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention\u2019s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO\u00ae (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug A",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "ACIP Votes to Expand Recommendation for Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Include Adults Aged 50 to 59 at Increased Risk of Disease",
                "url": "https://finance.yahoo.com/news/acip-votes-expand-recommendation-pfizer-201500828.html"
            }
        ],
        "avgScore": 0.4404,
        "pctChange": 0.004537135660944737
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
                "url": "https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html"
            },
            {
                "headline": "We recently published a list of Biotech Stocks Dominate Monday\u2019s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday\u2019s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street\u2019s major [\u2026]",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Why Viking Therapeutics, Inc.\u00a0(VKTX) Skyrocketed On Monday?",
                "url": "https://finance.yahoo.com/news/why-viking-therapeutics-inc-vktx-044028854.html"
            },
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            },
            {
                "headline": "BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out that it has argued that this program has received almost too much attention \u2013 not because obesity isn\u2019t important, but because this was only phase 1 data. Without danuglipron, Pfizer\u2019s obesity pipeline now consists of a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7269",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged",
                "url": "https://finance.yahoo.com/news/bofa-keeps-neutral-pfizer-danuglipron-150532621.html"
            },
            {
                "headline": "(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City\u2019s Housing ShortagePresident Donald Trump\u2019s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5994",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump Initiates Chips and Drug Probes\u00a0Ahead of More Tariffs",
                "url": "https://finance.yahoo.com/news/trump-announces-chips-drug-probes-204108780.html"
            },
            {
                "headline": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
                "url": "https://finance.yahoo.com/news/pfizer-halts-obesity-pill-development-165700605.html"
            }
        ],
        "avgScore": 0.06673749999999996,
        "pctChange": -0.017825294519186234
    },
    "4 14 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of the 11 Best Dividend Paying Stocks According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best dividend-paying stocks. Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by examining the [\u2026]",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9485",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) Among the Best Dividend Paying Stocks According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-among-best-142115898.html"
            },
            {
                "headline": "Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Sector Update: Health Care Stocks Rise Monday Afternoon",
                "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-180801475.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Chevron Corporation (CVX) and Stryker Corporation (SYK), as well as two micro-cap stocks Value Line, Inc. (VALU) and Sypris Solutions, Inc. (SYPR).",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Top Analyst Reports for Bank of America, Chevron & Stryker",
                "url": "https://finance.yahoo.com/news/top-analyst-reports-bank-america-211500618.html"
            },
            {
                "headline": "Pfizer tanks after liver injury kills obesity pill hopes--Lilly, Novo, and Viking surge as investors jump ship",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.743",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer's $130B Weight-Loss Dream Just Collapsed",
                "url": "https://finance.yahoo.com/news/pfizers-130b-weight-loss-dream-151831937.html"
            },
            {
                "headline": "Pfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6124",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Pfizer Abandons Obesity Pill After Trial Liver Injury",
                "url": "https://finance.yahoo.com/video/pfizer-abandons-obesity-pill-trial-140656016.html"
            },
            {
                "headline": "Pfizer  is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant.  The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug, called danuglipron.  Halting the drug\u2019s development means  Pfizer  still is unable to get a cut, for now, of the white-hot obesity market, which analysts say could reach $100 billion by the end of the decade.",
                "publication_date": "2025-04-14T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5719",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Pfizer Halts Development of Weight-Loss Pill",
                "url": "https://finance.yahoo.com/m/b3673b54-a975-32c1-a871-82025800a9e7/pfizer-halts-development-of.html"
            }
        ],
        "avgScore": -0.015080769230769227,
        "pctChange": 0.014466531766881651
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.\u2019s comments on the company\u2019s COVID shot approval delay. The Secretary of Health and Human Services pointed to the vaccine\u2019s single-antigen composition as the reason for the push back, adding that the FDA is \u201cshifting our priorities to multiple-antigen vaccines.\u201d SHIFTING PRIORITIES: The Food and Drug Administration is sitting on the decision to grant full approval for Novavax COVID-19 shot. In an interview wit",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Novavax slides after RFK Jr. casts doubts about COVID vaccine",
                "url": "https://finance.yahoo.com/news/novavax-slides-rfk-jr-casts-152014610.html"
            },
            {
                "headline": "We recently published a list of the 11 Cheap NYSE Stocks to Invest in According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks. On March 26, Jack Caffrey of JPMorgan Asset Management provided an analysis of market trends in [\u2026]",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3612",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) A Cheap NYSE Stock to Invest in According to Hedge Funds?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-cheap-nyse-203507561.html"
            },
            {
                "headline": "Pfizer (PFE) closed the most recent trading day at $21.91, moving +1.48% from the previous trading session.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer (PFE) Advances But Underperforms Market: Key Facts",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-advances-underperforms-market-214516632.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock",
                "url": "https://finance.yahoo.com/news/know-beyond-why-pfizer-inc-130014887.html"
            },
            {
                "headline": "Though the stock market is still historically pricey, a few phenomenal bargains have cropped up.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility",
                "url": "https://finance.yahoo.com/news/6-stocks-clear-price-dislocations-070600692.html"
            },
            {
                "headline": "Pfizer (PFE) closed the most recent trading day at $21.91, moving +1.48% from the previous trading session.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer (PFE) Advances But Underperforms Market: Key Facts",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-advances-underperforms-market-214516632.html"
            }
        ],
        "avgScore": 0.18994000000000003,
        "pctChange": 0.009584709871465072
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "PFE stock is likely to be a great pick for value investors, considering its cheap valuation, as well as for income investors due to its sky-high dividend yield.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pfizer Stock Falls to New 52-Week Low: Should You Buy the Dip?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-falls-52-week-134400344.html"
            },
            {
                "headline": "NEW YORK, April 10, 2025--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24, 2025. Pfizer has designed the virtual Annual Meeting to ensure that its shareholders who participate will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24",
                "url": "https://finance.yahoo.com/news/pfizer-invites-shareholders-attend-virtual-150000793.html"
            },
            {
                "headline": "A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%, while the baseline 10% tariffs remained in place for most countries. This reminded investors that the global trade environment remained volatile, limiting the potential for sustained market gains.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6249",
                "source": "StockStory",
                "ticker": "PFE",
                "title": "Select Medical, Phreesia, Eli Lilly, Pfizer, and Brink's Shares Are Falling, What You Need To Know",
                "url": "https://finance.yahoo.com/news/select-medical-phreesia-eli-lilly-171104703.html"
            },
            {
                "headline": "Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "S&P, Dow Jones Pharma Names Rattled \u2014 Again \u2014 On Trump's Tariffs Whiplash",
                "url": "https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s-p-dow-jones-pharma-names.html"
            },
            {
                "headline": "The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.25",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Vaxcyte Stock Plummets 56% in a Month: Here's the Reason",
                "url": "https://finance.yahoo.com/news/vaxcyte-stock-plummets-56-month-170700030.html"
            },
            {
                "headline": "General Motors, JD.com, Pfizer, StoneCo and Enersys have been highlighted in this Screen of The Week article.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Zacks.com featured highlights General Motors, JD.com, Pfizer, StoneCo and Enersys",
                "url": "https://finance.yahoo.com/news/zacks-com-featured-highlights-general-090000004.html"
            }
        ],
        "avgScore": 0.18951249999999997,
        "pctChange": 0.01482166246237205
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, JD, PFE, STNE and ENS are some such stocks.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Low Price-to-Book Stocks to Add to Your Portfolio in April",
                "url": "https://finance.yahoo.com/news/5-low-price-book-stocks-125800063.html"
            },
            {
                "headline": "Catalysts host Madison Mills and Trader Talk podcast host Kenny Polcari take a look at some of the day's top trending stocks. Apple (AAPL) is in focus after Microsoft (MSFT) replaced Apple as the most valuable company. Alibaba (BABA) reverses earlier gains after US tariffs went into effect. Drugmaker stocks, including Pfizer (PFE), Merck (MRK), and Eli Lilly (LLY), are falling after President Trump announced that pharmaceutical tariffs may be on the way. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7178",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Apple, Alibaba, drugmaker stocks: Trending Tickers",
                "url": "https://finance.yahoo.com/video/apple-alibaba-drugmaker-stocks-trending-144322260.html"
            },
            {
                "headline": "If you're a dividend investor, now can be an ideal time to go bargain-hunting.  The stock market is in the midst of a broad sell-off, with investors dumping all types of stocks, both bad ones and good ones.  Three dividend stocks that are near their 52-week lows and which may make for solid income-generating investments are Pfizer (NYSE: PFE), Lockheed Martin (NYSE: LMT), and Rogers Communications (NYSE: RCI).",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.0772",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now",
                "url": "https://finance.yahoo.com/news/3-high-yielding-dividend-stocks-093200831.html"
            },
            {
                "headline": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer were all down at least 2.5% in Wednesday midday trading.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK fell 2% or more in the U.S.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7506",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
                "url": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
            },
            {
                "headline": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5778",
                "source": "Simply Wall St.",
                "ticker": "PFE",
                "title": "Is Pfizer (NYSE:PFE) A Risky Investment?",
                "url": "https://finance.yahoo.com/news/pfizer-nyse-pfe-risky-investment-130015999.html"
            },
            {
                "headline": "Drugmaker stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), Merck (MRK), and Pfizer (PFE), are under pressure on Wednesday after President Trump announced that he may impose tariffs on pharmaceutical imports. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Yahoo Finance Video",
                "ticker": "PFE",
                "title": "Trump says pharmaceutical tariffs may be coming: What to know",
                "url": "https://finance.yahoo.com/video/trump-says-pharmaceutical-tariffs-may-141157823.html"
            }
        ],
        "avgScore": -0.1271,
        "pctChange": -0.04001776912803975
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9081",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Pfizer (PFE) Stock Undervalued Right Now?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-stock-undervalued-now-134010049.html"
            },
            {
                "headline": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "Investing.com",
                "ticker": "PFE",
                "title": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
                "url": "https://finance.yahoo.com/news/goldman-turns-cautious-major-pharma-130817424.html"
            },
            {
                "headline": "The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6754",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Down 62%, Should You Buy the Dip on Pfizer?",
                "url": "https://finance.yahoo.com/news/down-62-buy-dip-pfizer-084000869.html"
            },
            {
                "headline": "Pfizer  stock fell to the lowest closing price since 2012, putting its yield near 8%, after cautious comments from a  UBS  analyst ahead of the company\u2019s quarterly earnings on April 29.  Pfizer shares declined 3.5% to $21.84 after hitting a new 52-week low of $21.44.  All that has resulted in a generation of frustration for investors in what once was the top drug company in the world by market value.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Barrons.com",
                "ticker": "PFE",
                "title": "Pfizer Stock\u2019s Fall to \u201997 Level Lifts Yield Near 8%. Dividend Looks Safe.",
                "url": "https://finance.yahoo.com/m/21c833dc-2b10-33f0-afe2-439fc5c81233/pfizer-stock%E2%80%99s-fall-to-%E2%80%9997.html"
            },
            {
                "headline": "Goldman updates coverage across major U.S. drugmakers, citing exclusivity risks, pricing power, and pipeline outlooks",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie",
                "url": "https://finance.yahoo.com/news/biopharma-shakeup-goldman-boosts-j-175813148.html"
            },
            {
                "headline": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
                "url": "https://finance.yahoo.com/news/abbvies-rinvoq-gets-eu-nod-131500800.html"
            }
        ],
        "avgScore": 0.3437333333333333,
        "pctChange": 0.029761887087407044
    },
    "4 7 2025": {
        "importantArticles": [
            {
                "headline": "(Bloomberg) -- Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump\u2019s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpTrump Order on CDFI Fu",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8271",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump\u2019s Tariff Threat Sparks Race to Find US Drug Manufacturers",
                "url": "https://finance.yahoo.com/news/trump-tariff-threat-sparks-race-191812489.html"
            },
            {
                "headline": "(Bloomberg) -- Drug manufacturers are rushing to reshape their supply chains amid President Donald Trump\u2019s escalating tariff threats, leading to a potential windfall for contractors that make medications in the US.Most Read from BloombergHousing Agency Aims to Relocate Its DC HeadquartersThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpTrump Order on CDFI Fu",
                "publication_date": "2025-04-07T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8271",
                "source": "Bloomberg",
                "ticker": "PFE",
                "title": "Trump\u2019s Tariff Threat Sparks Race to Find US Drug Manufacturers",
                "url": "https://finance.yahoo.com/news/trump-tariff-threat-sparks-race-191812489.html"
            }
        ],
        "avgScore": -0.8271,
        "pctChange": -0.03490936975147238
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "FDA approves SNY's hemophilia therapy, fitusiran, and NVS' rare kidney disease drug, Vanrafia.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure",
                "url": "https://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-134600557.html"
            },
            {
                "headline": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Lightning Round: 8 Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Jim Cramer, host of Mad Money, discussed on Monday how investor sentiment surrounding tech stocks has shifted over [\u2026]",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE) \u2013 Jim Cramer Declares: \u2018Dead Money \u2013 Close the Casket!\u2019",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-jim-cramer-144529049.html"
            },
            {
                "headline": "Is Pfizer stock a sell now after HHS fired thousands of employees, putting new drug approvals in limbo?",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5574",
                "source": "Investor's Business Daily",
                "ticker": "PFE",
                "title": "Is Pfizer Stock A Sell As HHS Firings, Tariffs Cast A Pall On Pharma?",
                "url": "https://finance.yahoo.com/m/9a6f7dfd-febf-37fb-912a-e0504d778fbc/is-pfizer-stock-a-sell-as-hhs.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer\u2019s Lightning Round: 8 Stocks in Focus. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses. Jim Cramer, host of Mad Money, discussed on Monday how investor sentiment surrounding tech stocks has shifted over [\u2026]",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4939",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Pfizer Inc. (PFE) \u2013 Jim Cramer Declares: \u2018Dead Money \u2013 Close the Casket!\u2019",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-jim-cramer-144529049.html"
            },
            {
                "headline": "Johnson & Johnson and Pfizer are part of the Zacks top Analyst Blog",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2023",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "The Zacks Analyst Blog Highlights Johnson & Johnson and Pfizer",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-130400151.html"
            }
        ],
        "avgScore": -0.11177500000000001,
        "pctChange": -0.01480192262740811
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "In 2020, many companies tried to develop effective coronavirus vaccines, but two ended up succeeding and dominating the field: Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA).  If Pfizer and Moderna can bounce back, purchasing their shares now might be a great move -- but which is the more attractive option?  Pfizer has made important moves in the past few years that could pay off down the line.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9577",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna",
                "url": "https://finance.yahoo.com/news/better-beaten-down-stock-buy-123000684.html"
            },
            {
                "headline": "Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road.  As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.  Stocks normally trade at discounts when there are concerns or question marks about the company's future performance.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9325",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "2 Absurdly Cheap Stocks to Buy and Hold for Years",
                "url": "https://finance.yahoo.com/news/2-absurdly-cheap-stocks-buy-084000763.html"
            },
            {
                "headline": "Both JNJ & PFE expect their sales and profits to improve in 2025.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7003",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "JNJ vs. PFE: Which Drug Giant is a Better Buy Now?",
                "url": "https://finance.yahoo.com/news/jnj-vs-pfe-drug-giant-135900061.html"
            },
            {
                "headline": "(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent rights in its competing RSV shot Arexvy, according to a Thursday filing in Delaware federal court.  GSK and Pfizer said in the filing that they would dismiss the case with prejudice, which means it cannot be refiled.  GSK, Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration, with GSK's Arexvy responsible for the majority of U.S. RSV vaccine sales.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "GSK resolves patent lawsuit against Pfizer over RSV vaccines",
                "url": "https://finance.yahoo.com/news/gsk-resolves-patent-lawsuit-against-220317477.html"
            },
            {
                "headline": "Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year.  If you're a growth investor, you probably won't be interested in buying Pfizer stock.  Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0108",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Is Pfizer Stock a Buy?",
                "url": "https://finance.yahoo.com/news/pfizer-stock-buy-094700982.html"
            },
            {
                "headline": "GoodRx is trying to help pharmacies compete in a digital age, where they already face pressure on their margins.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "Yahoo Finance",
                "ticker": "PFE",
                "title": "GoodRx launches new e-commerce experience for prescriptions",
                "url": "https://finance.yahoo.com/news/goodrx-launches-new-e-commerce-experience-for-prescriptions-130044902.html"
            }
        ],
        "avgScore": 0.3982166666666667,
        "pctChange": -0.054343415085218984
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn\u2019t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won\u2019t be hit by any other tariff provisions, such as the 10% \u201cbaseline\u201d tariff.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Big Pharma Avoids Worst-Case Tariff Scenario",
                "url": "https://finance.yahoo.com/m/06d142db-a905-336a-a0df-f505312c37de/big-pharma-avoids-worst-case.html"
            },
            {
                "headline": "(Reuters) -Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its upcoming annual meeting, citing concerns about certain changes made to long-term awards to its CEO and others.  The modifications, including repeated changes to Pfizer's cash flow targets, and a lack of clarity about certain pipeline goals are concerning and undermine a \"pay-for-performance philosophy\", ISS said.  Annual incentives for executives are tied to achieving three financial goals, and payouts can be 30 percentage points higher or lower based on pipeline and ESG-related goals achieved, ISS said.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Reuters",
                "ticker": "PFE",
                "title": "Proxy adviser ISS recommends against Pfizer executive pay proposal",
                "url": "https://finance.yahoo.com/news/proxy-adviser-iss-recommends-pfizer-131020223.html"
            },
            {
                "headline": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
                "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-130009469.html"
            },
            {
                "headline": "Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.34",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters",
                "url": "https://finance.yahoo.com/news/pfe-mrk-lly-other-drug-134300035.html"
            },
            {
                "headline": "Pfizer\u2019s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer\u2019s products, like Eliquis (2027 to 2029) and Ibrance (2027), face \u201cpatent cliffs.\u201d That means their time for market exclusivity is",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "TipRanks",
                "ticker": "PFE",
                "title": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
                "url": "https://finance.yahoo.com/news/potential-stock-woe-ahead-pfizer-164324539.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Wednesday.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "PFE",
                "title": "Trending tickers: Tesla, Johnson & Johnson, CoreWeave, Newsmax and Raspberry Pi",
                "url": "https://finance.yahoo.com/news/tesla-johnson-johnson-coreweave-newsmax-raspberry-pi-trending-tickers-094114477.html"
            }
        ],
        "avgScore": 0.2131375,
        "pctChange": -0.0165991835930339
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?",
                "url": "https://finance.yahoo.com/news/pfizer-pfe-beat-estimates-again-161013995.html"
            },
            {
                "headline": "March winds bring April showers.  Seriously, there are several great ultra-high-yield dividend stocks to buy in April.  Ares Capital (NASDAQ: ARCC) offers such a high dividend yield, at 8.68%, that you might wonder if it's sustainable.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "3 Ultra-High-Yield Dividend Stocks to Buy in April",
                "url": "https://finance.yahoo.com/news/3-ultra-high-yield-dividend-095000907.html"
            },
            {
                "headline": "Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons.  The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.  Major stocks in the sector took notable hits, including but not at all limited to Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Eli Lilly (NYSE: LLY).",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4116",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Why Major Pharmaceutical Stocks Tumbled on Tuesday",
                "url": "https://finance.yahoo.com/news/why-major-pharmaceutical-stocks-tumbled-230939016.html"
            },
            {
                "headline": "NEW YORK, April 01, 2025--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO\u00ae, the company\u2019s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age. This expands the previous authorization for individuals aged 60 and older, and ABRYSVO now of",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Business Wire",
                "ticker": "PFE",
                "title": "European Commission Approves Pfizer\u2019s RSV Vaccine ABRYSVO\u00ae to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease",
                "url": "https://finance.yahoo.com/news/european-commission-approves-pfizer-rsv-070000511.html"
            },
            {
                "headline": "Dr. Mikael Dolsten, Pfizer\u2019s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Pharma Voice",
                "ticker": "PFE",
                "title": "Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the \u2018big questions\u2019",
                "url": "https://finance.yahoo.com/news/former-pfizer-cso-mikael-dolsten-080000530.html"
            },
            {
                "headline": "We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade in [\u2026]",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "PFE",
                "title": "Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts?",
                "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-most-undervalued-140133307.html"
            }
        ],
        "avgScore": 0.21872499999999997,
        "pctChange": 0.0065199609389937595
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration\u2019s top vaccine official has been pushed out. Shares in some larger drugmakers, such as GSK, also retreated.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out",
                "url": "https://finance.yahoo.com/m/2f2d481b-21ce-368a-a644-24dbc4039d4b/moderna-novavax-stocks-fall.html"
            },
            {
                "headline": "The health agency\u2019s top immunization official announced the move Monday in protest, citing Secretary Kennedy\u2019s \u2018misinformation and lies.\u2019",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "FastCompany",
                "ticker": "PFE",
                "title": "Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr.\u00a0anti-vax views",
                "url": "https://finance.yahoo.com/news/vaccine-stocks-tumble-moderna-novavax-183000390.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
                "url": "https://finance.yahoo.com/news/trending-stock-pfizer-inc-pfe-130013223.html"
            },
            {
                "headline": "Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?",
                "url": "https://finance.yahoo.com/news/trending-stock-pfizer-inc-pfe-130013223.html"
            },
            {
                "headline": "The health agency\u2019s top immunization official announced the move Monday in protest, citing Secretary Kennedy\u2019s \u2018misinformation and lies.\u2019",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "FastCompany",
                "ticker": "PFE",
                "title": "Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr.\u00a0anti-vax views",
                "url": "https://finance.yahoo.com/news/vaccine-stocks-tumble-moderna-novavax-183000390.html"
            },
            {
                "headline": "Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration\u2019s top vaccine official has been pushed out. Shares in some larger drugmakers, such as GSK, also retreated.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out",
                "url": "https://finance.yahoo.com/m/2f2d481b-21ce-368a-a644-24dbc4039d4b/moderna-novavax-stocks-fall.html"
            }
        ],
        "avgScore": 0.14106666666666667,
        "pctChange": -0.03157060900723182
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "The approval is based on open-label Phase III innovaTV 301 clinical trial data.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Pharmaceutical Technology",
                "ticker": "PFE",
                "title": "Genmab\u2019s Tivdak approved in Japan for advanced cervical cancer",
                "url": "https://finance.yahoo.com/news/genmab-tivdak-approved-japan-advanced-093443945.html"
            },
            {
                "headline": "The approval is based on open-label Phase III innovaTV 301 clinical trial data.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4767",
                "source": "Pharmaceutical Technology",
                "ticker": "PFE",
                "title": "Genmab\u2019s Tivdak approved in Japan for advanced cervical cancer",
                "url": "https://finance.yahoo.com/news/genmab-tivdak-approved-japan-advanced-093443945.html"
            }
        ],
        "avgScore": 0.4767,
        "pctChange": 0.005156726411596922
    },
    "3 27 2025": {
        "importantArticles": [
            {
                "headline": "Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.3% and",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7506",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Sector Update: Health Care Stocks Advance Late Afternoon",
                "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-195816814.html"
            },
            {
                "headline": "Donald Trump\u2019s justice department is investigating claims that Pfizer delayed positive news about its Covid-19 vaccine until after the 2020 election.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "The Telegraph",
                "ticker": "PFE",
                "title": "GSK accuses Pfizer of delaying Covid vaccine result until after US election",
                "url": "https://finance.yahoo.com/news/gsk-accuses-pfizer-delaying-covid-140642612.html"
            },
            {
                "headline": "The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive",
                "url": "https://finance.yahoo.com/news/merck-gets-ec-nod-21-153400793.html"
            },
            {
                "headline": "Healthcare stocks have been out of vogue with investors since late 2022.  Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted.  Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3291",
                "source": "Motley Fool",
                "ticker": "PFE",
                "title": "Why Pfizer Is My Largest Healthcare Position",
                "url": "https://finance.yahoo.com/news/why-pfizer-largest-healthcare-position-104500478.html"
            },
            {
                "headline": "(Updates with Pfizer's response to a request for comment from MT Newswires in the second and third p",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Update: Market Chatter: US Prosecutors Investigate Tip on Pfizer Vaccine",
                "url": "https://finance.yahoo.com/news/market-chatter-us-prosecutors-investigate-123554313.html"
            },
            {
                "headline": "(Update with Pfizer's response to a request for comment.) Pfizer (PFE) sold $20 billion of drugs",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "MT Newswires",
                "ticker": "PFE",
                "title": "Update: Sen. Ron Wyden Accuses Pfizer of Tax Dodging After Concluding Investigation",
                "url": "https://finance.yahoo.com/news/sen-ron-wyden-accuses-pfizer-185224734.html"
            }
        ],
        "avgScore": 0.2223,
        "pctChange": 0.007996755448241034
    },
    "3 26 2025": {
        "importantArticles": [
            {
                "headline": "Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful Covid-19 vaccine until after the 2020 election.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "Pfizer Stock Slips After Report on Vaccine Timing Probe",
                "url": "https://finance.yahoo.com/m/7edf436c-1971-3b95-973d-6615a7f6abe3/pfizer-stock-slips-after.html"
            },
            {
                "headline": "ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "CNW Group",
                "ticker": "PFE",
                "title": "ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program",
                "url": "https://finance.yahoo.com/news/viiv-healthcare-announces-reimbursement-apretude-130100708.html"
            },
            {
                "headline": "The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1531",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine",
                "url": "https://finance.yahoo.com/m/fe9864d2-2e39-3113-b81a-bb1d03b92d18/u-s-prosecutors-probe-tip.html"
            },
            {
                "headline": "In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Here's Why Pfizer (PFE) Fell More Than Broader Market",
                "url": "https://finance.yahoo.com/news/heres-why-pfizer-pfe-fell-214515204.html"
            },
            {
                "headline": "The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1531",
                "source": "The Wall Street Journal",
                "ticker": "PFE",
                "title": "U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine",
                "url": "https://finance.yahoo.com/m/fe9864d2-2e39-3113-b81a-bb1d03b92d18/u-s-prosecutors-probe-tip.html"
            },
            {
                "headline": "ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "CNW Group",
                "ticker": "PFE",
                "title": "ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program",
                "url": "https://finance.yahoo.com/news/viiv-healthcare-announces-reimbursement-apretude-130100708.html"
            }
        ],
        "avgScore": 0.227925,
        "pctChange": -0.007933314670923713
    },
    "3 25 2025": {
        "importantArticles": [
            {
                "headline": "Undervalued, Strong Pipeline, Positioned for Growth Potential.",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7096",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer: Undervalued Defensive Play",
                "url": "https://finance.yahoo.com/news/pfizer-undervalued-defensive-play-211251970.html"
            },
            {
                "headline": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5423",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Large Drug Stocks to Watch as Industry Recovers",
                "url": "https://finance.yahoo.com/news/5-large-drug-stocks-watch-104700001.html"
            },
            {
                "headline": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "url": "https://finance.yahoo.com/news/broadcom-crown-castle-box-highlighted-062000144.html"
            },
            {
                "headline": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "Broadcom and Crown Castle in the Box have been highlighted as Zacks Bull and Bear of the Day",
                "url": "https://finance.yahoo.com/news/broadcom-crown-castle-box-highlighted-062000144.html"
            },
            {
                "headline": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5423",
                "source": "Zacks",
                "ticker": "PFE",
                "title": "5 Large Drug Stocks to Watch as Industry Recovers",
                "url": "https://finance.yahoo.com/news/5-large-drug-stocks-watch-104700001.html"
            },
            {
                "headline": "Undervalued, Strong Pipeline, Positioned for Growth Potential.",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7096",
                "source": "GuruFocus.com",
                "ticker": "PFE",
                "title": "Pfizer: Undervalued Defensive Play",
                "url": "https://finance.yahoo.com/news/pfizer-undervalued-defensive-play-211251970.html"
            }
        ],
        "avgScore": 0.4173,
        "pctChange": -0.013307247073992737
    },
    "coef": 0.41818181818181815,
    "avgCoef": 0.01611642298480064,
    "similar": {
        "ENPH": 0.5818181818181818,
        "PBR": 0.5766233766233767,
        "CSX": 0.5714285714285714,
        "F": 0.5662337662337662
    }
}